# US 2006/0153772 A1 · Contextual fear conditioning for predicting immunotherapeutic efficacy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2006/0153772 A1
- Document ID: US20060153772A1
- Status: Published application
- Kind: A1
- Application number: 11/305,889
- Filed: 2005-12-15
- Published: 2006-07-13
- Earliest claimed: 2004-12-15
- Assignees: Wyeth
- Inventors: Jack Jacobsen
- Web page: https://patentgrep.com/patent/US20060153772A1

## CPC

- A61K 49/0008: {Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The invention provides methods for determining effective immunotherapeutic agents which may be used for the treatment of cognitive disorders.

## Claims

### Claim 1

A method for identifying an immunotherapeutic agent effective for improving cognition in a subject suffering from a cognitive disorder, comprising the steps of:
(i) administering a test immunotherapeutic agent to a model animal of the disorder wherein the model animal exhibits a cognitive deficit;
(ii) conducting at least one training session in which the model animal is administered a context-dependent stimulus that is paired with an aversive stimulus; and
(iii) conducting at least one testing session in which the model animal is administered a context-dependent stimulus in the absence of the aversive stimulus,
whereby an improvement in context-dependent memory identifies the immunotherapeutic agent as effective for improving cognition in the subject.

### Claim 2

A method for identifying an immunotherapeutic agent effective for improving cognition in a subject suffering from a cognitive disorder, comprising the steps of:
(i) administering a test immunotherapeutic agent to a model animal of the disorder wherein the model animal exhibits a cognitive deficit;
(ii) conducting at least one training session in which the model animal is administered a context-dependent stimulus that is paired with an aversive stimulus;
(iii) conducting at least one testing session in which the model animal is administered a context-dependent stimulus in the absence of the aversive stimulus; and
(iv) comparing a context-dependent fear response of the model animal in step (iii) to an appropriate control,
whereby an improvement in context-dependent fear response identifies the immunotherapeutic agent as effective for improving cognition in the subject.

### Claim 3 (depends on 1, 2)

The method of claim 1 or 2, wherein the cognitive disorder is an amyloidogenic disorder.

### Claim 4 (depends on 3)

The method of claim 3, wherein the amyloidogenic disorder is Alzheimer's disease.

### Claim 5 (depends on 1, 2)

The method of claim 1 or 2, wherein the model animal is selected from the group consisting of a PDAPP mouse, a Tg2576 mouse, a TgAPP22 mouse, a TgAPP/LD/2 mouse, a PSEN-1 A246E mouse, a PSEN-1 DeltaE9 mouse, a Tg2576+PSEN-1 mouse, a TgHu/MoAPP A246E +PSEN-1 mouse, a TgHu/MoAPP DeltaE9+PSEN-1 mouse, a TgCDNR8 mouse, a PSAPP mouse, and a 3xTg-AD mouse.

### Claim 6 (depends on 1, 2)

The method of claim 1 or 2, wherein the model animal is at least 20 weeks of age prior to administration of the test immunotherapeutic agent.

### Claim 7 (depends on 1, 2)

The method of claim 1 or 2, wherein the model animal is at least 10 weeks of age prior to administration of the test immunotherapeutic agent.

### Claim 8 (depends on 1, 2)

The method of claim 1 or 2, wherein the cognitive deficit is an impairment in procedural learning and/or memory.

### Claim 9 (depends on 8)

The method of claim 8, wherein the impairment in procedural learning and/or memory is contextual-dependent.

### Claim 10 (depends on 8)

The method of claim 8, wherein the impairment in procedural learning and/or memory is cue-dependent.

### Claim 11 (depends on 1, 2)

The method of claim 1 or 2, wherein the aversive stimulus is a footshock.

### Claim 12 (depends on 1, 2)

The method of claim 1 or 2, wherein two or fewer training sessions are suitable to condition the model animal to the aversive stimulus.

### Claim 13 (depends on 1)

The method of claim 1, wherein the model animal is administered a cue-dependent stimulus paired with the aversive stimulus during the training session.

### Claim 14 (depends on 13)

The method of claim 13, wherein the model animal is administered a cue-dependent stimulus in the absence of the aversive stimulus during the testing session.

### Claim 15 (depends on 13, 14)

The method of claim 13 or 14, wherein the cue conditioning stimulus is an auditory cue.

### Claim 16 (depends on 1, 2)

The method of claim 1 or 2, wherein the context conditioning stimulus is an altered cage.

### Claim 17 (depends on 2)

The method of claim 2, wherein the fear response is a freezing behavior.

### Claim 18 (depends on 2)

The method of claim 2, wherein the suitable control is a wild-type animal administered the test immunotherapeutic.

### Claim 19 (depends on 18)

The method of claim 18, wherein the improvement in the context-dependent fear response is a nonsignificant difference in status of impairment of the model animal as compared to the wild-type animal.

### Claim 20 (depends on 2)

The method of claim 2, wherein the suitable control is a model animal that is not administered the test immunotherapeutic agent.

### Claim 21 (depends on 20)

The method of claim 20, wherein the improvement in the context-dependent fear response is a significant difference in deficit reversal as compared to the model animal that is not administered the test immunotherapeutic agent.

### Claim 22 (depends on 1, 2)

The method of claim 1 or 2, wherein steps (i), (ii), (iii), or (iv) are repeated one to five times.

### Claim 23 (depends on 1, 2)

The method of claim 1 or 2, wherein the model animal is administered multiple doses of a test immunotherapeutic agent.

### Claim 24 (depends on 22)

The method of claim 22, wherein steps (i), (ii), (iii), or (iv) are repeated with a different concentration of the test immunotherapeutic agent.

### Claim 25 (depends on 1, 2)

The method of claim 1 or 2, wherein step (iii) is performed within 24 hours of step (i).

### Claim 26 (depends on 1, 2)

The method of claim 1 or 2, wherein the test immunotherapeutic agent is a passive immunotherapeutic agent.

### Claim 27 (depends on 26)

The method of claim 26, wherein the test immunotherapeutic agent is an Aβ antibody.

### Claim 28 (depends on 27)

The method of claim 27, wherein the Aβ antibody is administered in a single dose.

### Claim 29 (depends on 1, 2)

The method of claim 1 or 2, wherein the test immunotherapeutic agent is selected from the group consisting of a humanized Aβ antibody, a chimeric Aβ antibody, and a variant Aβ antibody, or antigen binding fragments thereof.

### Claim 30 (depends on 29)

The method of claim 29, wherein the test immunotherapeutic agent is administered in a single dose.

### Claim 31

A method for identifying an immunotherapeutic agent effective in neutralizing one or more toxic soluble forms of Aβ peptide, comprising the steps of:
(i) administering a test immunotherapeutic agent to a model animal of an amyloidogenic disorder wherein the model animal exhibits a cognitive deficit;
(ii) conducting at least one training session in which the model animal is administered a context-dependent stimulus that is paired with an aversive stimulus; and
(iii) conducting at least one testing session in which the model animal is administered a context-dependent stimulus in the absence of the aversive stimulus,
whereby an improvement in context-dependent memory identifies the immunotherapeutic agent as effective in neutralizing one or more toxic soluble forms of Aβ peptide.

### Claim 32 (depends on 31)

The method of claim 31, wherein the test immunotherapeutic agent is further tested for its ability to bind to and/or clear insoluble forms of Aβ peptide.

### Claim 33 (depends on 32)

The method of claim 32, whereby a greater than 50% reduction in the size and number of amyloid deposits identifies the immunotherapeutic agent as effective in clearing plaque.

### Claim 34

A method of identifying an epitope in an Aβ peptide comprising the steps of:
(i) administering a fragment of the Aβ peptide to a model animal of an amyloidogenic disorder wherein the model animal exhibits a cognitive deficit;
(ii) conducting at least one training session in which the model animal is administered a context-dependent stimulus that is paired with an aversive stimulus; and
(iii) conducting at least one testing session in which the model animal is administered a context-dependent stimulus in the absence of the aversive stimulus,
whereby an improvement in context-dependent memory identifies an epitope in the Aβ peptide.

### Claim 35 (depends on 34)

The method of claim 34, wherein the method is repeated with a truncated form of the Aβ peptide.

### Claim 36 (depends on 35)

The method of claim 35, wherein the Aβ peptide is used as an active immunotherapeutic agent for improving cognition in a subject.

### Claim 37 (depends on 35)

The method of claim 35, wherein the Aβ peptide used to generate an antibody.

### Claim 38 (depends on 37)

The method of claim 37, wherein the antibody is used as a passive immunotherapeutic agent for improving cognition in a subject.

### Claim 39

A method for identifying an immunotherapeutic agent effective for improving cognition in a subject suffering from a cognitive disorder, the method comprising the steps of:
(i) administering an Aβ peptide to a model animal of an amyloidogenic disorder wherein the model animal exhibits a cognitive deficit;
(ii) conducting at least one training session in which the model animal is administered a context-dependent stimulus that is paired with an aversive stimulus; and
(iii) conducting at least one testing session in which the model animal is administered a context-dependent stimulus when the in vivo concentration of the test immunotherapeutic agent is more than 50% of the dose administered in step (i),
whereby an improvement in context-dependent memory identifies the immunotherapeutic agent as effective in improving cognition in the subject.

### Claim 40

A method for identifying an immunotherapeutic agent effective for improving cognition in a subject suffering from a cognitive disorder, the method comprising the steps of:
(i) administering a test immunotherapeutic agent to a model animal of the disorder wherein the model animal exhibits a cognitive deficit;
(ii) conducting at least one training session in which the model animal is administered a context-dependent stimulus that is paired with an aversive stimulus;
(iii) conducting at least one testing session in which the model animal is administered a context-dependent stimulus in the absence of the aversive stimulus; and
(iv) comparing a context-dependent fear response of the model animal in step (iii) to a context-dependent fear response of a wild-type animal administered the test immunotherapeutic,
whereby a nonsignificant difference in status of impairment of the model animal as compared to the wild-type animal identifies the test immunotherapeutic agent as effective in improving cognition in the subject.

### Claim 41

A method for identifying an immunotherapeutic agent effective for improving cognition in a subject suffering from a cognitive disorder, the method comprising the steps of:
(i) administering a test immunotherapeutic agent to a model animal of the disorder wherein the model animal exhibits a cognitive deficit;
(ii) conducting at least one training session in which the model animal is administered a context-dependent stimulus that is paired with an aversive stimulus;
(iii) conducting at least one testing session in which the model animal is administered a context-dependent stimulus in the absence of the aversive stimulus; and
(iv) comparing a context-dependent fear response of the model animal in step (iii) to a context-dependent fear response of a model animal that is not administered the test immunotherapeutic agent,
whereby a significant difference in deficit reversal of the model animal in step (iii) as compared to the model animal that is not administered the test immunotherapeutic agent identifies the test immunotherapeutic agent as effective in improving cognition.

### Claim 42

A method for identifying an immunotherapeutic agent effective for improving cognition in a subject suffering from a cognitive disorder, the method comprising the steps of:
(i) administering a test immunotherapeutic agent to a model animal of the disorder wherein the model animal exhibits a cognitive deficit;
(ii) conducting at least one training session in which the model animal is administered a context-dependent stimulus that is paired with an aversive stimulus;
(iii) conducting at least one testing session in which the model animal is administered a context-dependent stimulus in the absence of the aversive stimulus; and
(iv) comparing a context-dependent fear response of the model animal in step (iii) to a context-dependent fear response of a wild-type animal administered the test immunotherapeutic;
(v) comparing a context-dependent fear response of the model animal in step (iii) to a context-dependent fear response of a model animal that is not administered the test immunotherapeutic agent,
whereby a nonsignificant difference in status of impairment of the model animal as compared to the wild-type animal and a significant difference in deficit reversal of the model animal in step (iii) as compared to the model animal that is not administered the test immunotherapeutic agent identifies the test immunotherapeutic agent as effective in improving cognition.
